Hot-selling Lilly drug gets OK for second use
Taltz, launched in 2016 to treat plaque psoriasis, won approval from the Food and Drug Administration for a second indication—treating adults with a form of arthritis.
Taltz, launched in 2016 to treat plaque psoriasis, won approval from the Food and Drug Administration for a second indication—treating adults with a form of arthritis.
The Food and Drug Administration wants to help patients get faster access to promising cancer treatments, FDA Commissioner Scott Gottlieb told House lawmakers Thursday.
Pharmaceutical companies have introduced medicines to treat dependence, reverse overdoses and deal with opioid side effects. But few effective and economically viable alternatives to addictive painkillers have emerged from the laboratory.
Caprice Bearden, 63, of Carmel pleaded guilty in U.S. District Court to one count of conspiracy to defraud the United States and nine misdemeanor counts related to the sale of adulterated drugs, including painkillers that were used on hospitalized infants.
The rate of deaths increased slightly in every quarter of 2016, indicating an accelerating epidemic. That crisis has been driven by opioid abuse.
A pharmacist at a facility whose tainted drugs sparked a nationwide meningitis outbreak that killed 76 people, including five people in Indiana, was cleared Wednesday of murder but was convicted of other crimes.
The Indianapolis drugmaker said it will use the money to replace an existing line that fills vials for Humalog and Humulin and to prepare for new insulin products.
Indianapolis-based insurer Anthem Inc. said it will set up its own pharmacy benefits management unit, signaling a final break with Express Scripts Holding Co. after the health insurer accused Express of overcharging it by billions of dollars.
Before joining Eli Lilly and Co., Alex Azar served as the general counsel and deputy secretary of Health and Human Services Administration under President George Bush.
The deal comes as Express Scripts faces challenges on a number of fronts, including the possible loss of its largest customer, Indianapolis-based health-insurance giant Anthem Inc.
California has passed a law requiring pharmaceutical companies to explain their price increases, escalating the state-by-state battle between lawmakers trying to bring more transparency to the industry’s practices and drugmakers that oppose the efforts.
Harry Zhang pleaded guilty to two felonies this month after charged with illegally obtaining prescriptions from Canada and Germany and reselling them in China.
Thirty-four new drugs—treating everything from cancer to rare genetic diseases—have been approved so far this year. That’s on pace to nearly double last year’s approvals.
The city of Indianapolis plans to file a “robust lawsuit” against several drug companies, Mayor Joe Hogsett announced Thursday morning.
The U.S. Food and Drug Administration is opening a new front in its efforts to reduce high drug prices by encouraging development of generic versions of hard-to-make medicines.
After struggling for more than 20 years to develop cancer drugs without success, West Lafayette-based Endocyte Inc. is pausing it own R&D efforts to concentrate on a potential blockbuster drug from a German chemical company.
The appointments mark the latest changes in the Indianapolis-based drugmaker’s executive suite since David Ricks took over as CEO in January.
U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
From January to July, the agency sent 265 warning letters to companies, notifying them of what it alleged to be serious violations of federal rules. That’s the lowest tally for the first seven months of any year since 2008.
The panel will help promote collaboration among treatment providers, criminal justice systems and child welfare agencies.